Paychex's Dividend Is Covered, but Small-Business Hiring Is the Tripwire

Wall Street’s latest nuclear-energy calls show that support for the sector does not translate into equal confidence in every stock. Analysts remained constructive on established power producers while cutting targets more sharply for developers and fuel companies whose valuations depend on future milestones.

Citi lowered its Oklo target to $33 from $57.50 and kept a Neutral rating. The new target still implied upside from the cited market price, but the reduction reflects a lower valuation for an advanced-reactor developer that has not yet reached commercial operation. Citi also cut NuScale Power’s target to $4 from $6.50 and maintained a Sell rating, implying downside in the original report.

Morgan Stanley raised its Constellation Energy target to $378 from $369 and kept an Overweight rating. The firm linked the outlook to utility fundamentals and the political debate around data-center power demand. Constellation owns operating nuclear plants, so its earnings are tied to actual generation, power prices and customer contracts rather than only future reactor deployment.

The analyst split is a reminder that nuclear demand can be bullish while individual equity risk remains very different.

Raymond James reduced its Vistra target to $176 from $182 but maintained a Strong Buy rating. The firm argued that concerns about ERCOT forward prices, regulation and slower data-center contracting were already reflected in the stock, while agreements with Meta and Amazon Web Services, a pending acquisition and PJM fundamentals offered support.

Centrus Energy received a sharper target cut. Roth Capital lowered its target to $115 from $188 and kept a Neutral rating, warning that third-quarter results could disappoint after the company acquired Westerman Holdings for $11 million. Centrus is exposed to uranium enrichment and fuel-cycle policy, creating a different risk profile from power producers.

The common sector catalyst is rising electricity demand from data centers and electrification. The differences are timing and financing. Operating generators can sell power today. Advanced-reactor developers must pass licensing, construction and funding milestones. Fuel suppliers depend on contract timing, government policy and capacity expansion.

Investors should avoid using a single nuclear thesis for all five stocks. The next earnings reports should be judged on company-specific evidence: contracted power prices for Constellation and Vistra, licensing and cash runway for Oklo and NuScale, and order visibility for Centrus.

Venture Global’s agreements with GE Vernova create a potentially large pipeline of grid and power equipment, but investors should not treat the full estimated value as booked revenue. The arrangements reserve manufacturing capacity and establish terms for future purchases. Most of the equipment becomes binding only when Venture Global places purchase orders.

The grid agreement covers transformers and gas-insulated switchgear for as many as 21 power-island projects. Five equipment packages have been reserved, with purchase orders expected to begin in late 2026. A separate power agreement includes a planned first power-island order by year-end 2026 and reservations for eight more units, with orders expected from early 2027.

The SEC filing makes the condition clear: the ability to reserve capacity expires on staggered dates from October 2027 through October 2029 if definitive agreements are not completed. The widely cited figure of roughly $17.2 billion assumes that all contemplated orders proceed and includes equipment from more than one supplier. The split attributable to GE Vernova was not disclosed.

The reservations are commercially meaningful, but they are not equivalent to a firm $17.2 billion order backlog.

The opportunity arrives as GE Vernova’s Electrification backlog has expanded sharply. Management said the segment’s backlog reached $45 billion, up from $6 billion at the end of 2021. That growth reflects strong demand for transformers, switchgear and other equipment needed to connect data centers and power projects to the grid.

Execution remains the critical test. GE Vernova completed its acquisition of the remaining stake in Prolec GE, but Prolec reported second-quarter revenue of $859 million and a $57 million pretax loss. Management believes the business can outperform earlier expectations by 2028, yet the current loss shows that revenue growth does not automatically translate into profit.

Valuation also leaves little room for disappointment. The original analysis placed GE Vernova at more than 44 times forward normalized earnings, well above mature electrification peers. If Venture Global converts reservations into orders and margins improve, the premium can be supported. If orders are delayed or integration costs persist, the same premium increases downside.

Investors should watch the first purchase orders, the pace of backlog conversion and Prolec’s margins. Those milestones will show whether a compelling demand story is becoming durable cash flow.

CVS Health’s operating recovery gives investors more room to focus on the next set of risks. Second-quarter 2026 revenue reached $106.1 billion, operating income was $4.7 billion and the Health Care Benefits segment’s adjusted operating income rose 85.5% to $2.43 billion. The medical benefit ratio improved to 87.4% from 89.9%.

Those figures show that insurance profitability is healing, but three issues could determine whether the improvement lasts.

The first is the 340B drug-pricing program. Changes to how manufacturers, pharmacies and covered entities share discounts can affect the economics of CVS’s pharmacy and pharmacy-benefit operations. Policy proposals, litigation and implementation details can move the impact substantially, so investors should distinguish a final rule from a proposal or court challenge.

The second is client retention at Caremark. Pharmacy-benefit contracts are large and often renewed on multi-year cycles. Losing a major client can reduce prescription volume and purchasing scale, while aggressive pricing to retain business can protect revenue at the expense of margin. Membership figures, new wins and disclosures about contract profitability are more informative than headline revenue alone.

The third is Medicare Advantage quality ratings. Star ratings influence bonus payments and can affect enrollment. A change in ratings can take time to flow through financial statements because the payment year may lag the measurement period. Investors should track which plans are affected, how many members they cover and when any payment change begins.

CVS’s improved second-quarter results provide a stronger base, but policy, client retention and Medicare ratings can still change the trajectory quickly.

The Health Services segment also improved, with adjusted operating income of $1.73 billion, up 10%. That performance helps offset risk elsewhere, yet the company’s integrated model creates connections among insurance, pharmacy benefits, retail pharmacies and care delivery. A problem in one segment can affect volumes and economics in another.

The next six months should be evaluated through specific evidence: final regulatory text, named contract wins or losses, member counts, star-rating distributions and updated cash-flow guidance. Broad statements about political risk are not enough.

CVS has raised its full-year outlook, which gives the recovery credibility. The stock’s rerating will depend on whether management can preserve that progress while navigating policy changes and contract renewals. The key question is no longer only whether insurance margins can rebound; it is whether the wider platform can convert the rebound into durable cash flow without a new setback elsewhere.

CBRE is facing a renewed talent challenge in Chicago as experienced brokers move to Cushman & Wakefield and JLL. The departures matter because commercial real-estate advisory is a relationship business: senior producers carry client trust, local market knowledge and transaction pipelines that can take years to build.

Bisnow reported that three more professionals left CBRE for Cushman & Wakefield, continuing a series of departures. Separately, JLL said it added six Chicago office and life-sciences professionals from CBRE. JLL described the group as bringing 75 years of combined experience and work involving more than 75 million square feet and $50 billion of transaction value.

Those figures describe career experience, not revenue transferred to JLL. Clients are free to choose advisers, contracts may not move with individuals, and transaction volume is not the same as brokerage income. Still, the scale of the recruited teams shows why rivals view the hires as strategic.

The immediate value lies in relationships and deal flow, but the ultimate financial effect depends on which clients and assignments follow the brokers.

For CBRE, the risk is concentrated rather than company-wide. CBRE is the world’s largest commercial real-estate services group and operates across leasing, capital markets, property management, facilities and investment management. A handful of Chicago departures will not determine the entire company’s results. They can, however, weaken a local practice, create retention pressure and force the firm to spend more on recruiting or compensation.

For Cushman & Wakefield and JLL, the hires can accelerate growth without waiting for junior staff to build networks. The benefit will be strongest if the teams bring active assignments and cross-sell clients into broader services. The cost is compensation, integration and the possibility that expected business does not materialize.

Investors should look for evidence beyond headcount announcements. Market-share changes, disclosed transaction wins, producer retention and margin trends in advisory businesses will show whether the moves create lasting value. No financial terms or revenue impact were disclosed in the materials reviewed.

The episode is a reminder that human capital is a real asset in brokerage, even when it does not appear on the balance sheet. CBRE retains enormous scale, but the Chicago departures give competitors a chance to convert experienced teams into new revenue. The next proof will come from client mandates, not from the announcements themselves.

Kimberly-Clark and Unilever are both defensive consumer companies, but their dividend cases are built differently. Kimberly-Clark offered the higher yield in the original comparison, while Unilever brought a broader mix of categories, brands and markets.

Kimberly-Clark’s second-quarter adjusted earnings per share from continuing operations reached $1.80, up 10.4% from a year earlier. That improvement supports dividend coverage, but investors should still examine the sources of growth. Cost savings and pricing can lift earnings even when volumes are weak, while sustainable growth usually requires a better balance among volume, price and product mix.

Unilever reported first-half free cash flow of €1.5 billion, up from €1.1 billion a year earlier. Free cash flow is an important dividend measure because it shows the cash left after operating needs and capital spending. The company’s global scale spreads exposure across personal care, beauty, home care, nutrition and ice cream, though the planned portfolio changes and currency movements can make comparisons more complicated.

Kimberly-Clark offers more current income, while Unilever offers broader diversification and a larger set of brands and markets.

The higher yield is not automatically the better bargain. Kimberly-Clark depends heavily on tissue and personal-care categories, which can be pressured by pulp costs, private-label competition and retailer bargaining power. Unilever faces slower-moving portfolios, emerging-market volatility and the challenge of managing hundreds of brands efficiently.

US investors also receive Unilever dividends through a multinational structure, which adds exchange-rate and tax considerations. Kimberly-Clark’s US-dollar dividend is simpler, but its payout still depends on maintaining margins in categories where consumers can trade down.

The comparison should focus on three measures: free cash flow after capital spending, dividend growth per share and the proportion of earnings paid out. A company can maintain a dividend during a difficult period by borrowing, but that does not make the distribution healthy.

Kimberly-Clark may suit an investor who values a higher current yield and a focused essential-products portfolio. Unilever may be more attractive to someone who accepts a lower yield for geographic and category diversification. Recent results show cash and earnings support at both companies, but neither removes the need to watch volumes, input costs and currency. The better income stock is the one whose risks complement the rest of the portfolio.